Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Alkermes Plc (NQ: ALKS)
20.95 USD  +0.30 (+1.45%)
Official Closing Price  /  Updated: 5:11 PM EST, Dec 6, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,053,800
Open 20.84
Bid (Size) 21.00 (1)
Ask (Size) 21.38 (1)
Prev. Close 20.65
Today's Range 20.75 - 21.13
52wk Range 17.11 - 37.75
Shares Outstanding 145,827,889
Dividend Yield N/A
Performance
YTD
-28.03%
-28.03%
1 Month
+6.35%
+6.35%
3 Month
+3.41%
+3.41%
6 Month
-8.23%
-8.23%
1 Year
-39.75%
-39.75%
Top News
More News
Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, Dec. 3,... Read More
from PR Newswire
Alkermes Completes Acquisition of Rodin Therapeutics
-- Acquisition Expands Alkermes' Research and Development Efforts to Include Small Molecule Therapeutics for Synaptopathies -- Read More
from PR Newswire
More News
Read More
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
from PR Newswire
Alkermes to Acquire Rodin Therapeutics
from PR Newswire
Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences
from PR Newswire
Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™
from PR Newswire
Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
from PR Newswire
Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
from PR Newswire
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
from GlobeNewswire News Releases
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
from PR Newswire
Uptrend Call Working As Alkermes Plc Stock Rises 5.7% (ALKS)
from Comtex SmarTrend® News Briefs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.